Pharmafile Logo
Pharmafocus logo
Advanced Search

generics

Showing 15 posts of 209 posts found.

lyrica

High Court rules against Pfizer in Lyrica patent case

September 10, 2015
Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, anxiety, epilepsy, generics, neuropathic pain, pregabalin

The High Court of England and Wales today ruled against Pfizer in the patent battle with Actavis on Pfizer’s blockbuster …

News

Lundbeck sheds 1,000 jobs in £284 million restructure

August 20, 2015
Manufacturing and Production, Sales and Marketing Lundbeck, generics, job losses, patents, redundancies, restructure, restructuring

Lundbeck is cutting a thousand jobs globally as part of a restructuring programme to significantly lower its cost and focus …

News
Pfizer image

Pfizer offers to pay for UK Lyrica switches

August 13, 2015
Lyrica, NHS England, Pfizer, generics, neuropathic pain, patents, pregabalin

Pfizer is to pay the administrative costs of GPs to switch patients to Lyrica from generic versions of pregabalin, as …

News

Pfizer and Flynn rapped for overcharging on anti-epilepsy drug

August 6, 2015
Manufacturing and Production, Sales and Marketing CMA, Drug pricing, Flynn Pharma, Pfizer, competitions markets authority, epilepsy, generics, phenytoin, pricing

Pharma firms Pfizer and Flynn Pharma have been accused by the UK’s competition watchdog of charging ‘excessive and unfair’ prices …

News
allergan

Teva to switch generics focus to Allergan

July 27, 2015
Sales and Marketing Allergan, Teva, generics, mergers and acquisitions, pharma mergers and acquisitions

Teva is in negotiations to buy Allergan’s generics division for upwards of $40 billion, according to reports. The generics firm …

News
Teva image

Teva ‘to increase Mylan bid to $43bn’

July 7, 2015
Sales and Marketing M&A, MA, Mylan, Teva, generics

Israeli drugmaker Teva is considering whether to up its bid for US rival firm Mylan, with reports that it could …

News
Mylan image

Mylan tells Teva to ‘stop playing games’ and make firm bid

June 2, 2015
Manufacturing and Production, Sales and Marketing M&A, MA, Mylan, Teva, generics

Mylan has written another strongly-worded letter to Teva, this time accusing the Israeli firm of ‘playing games’ and violating US …

News
Teva image

Teva forges ahead with Mylan pursuit

May 6, 2015
Sales and Marketing Mylan, Perrigo, Teva, generics

Teva has reinforced its commitment to buy Mylan despite previous rejection and only days after Mylan upped its own bid …

News
teva_copy

M&A drama continues as Mylan rejects Teva

April 28, 2015
Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers

Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …

News
Teva image

Teva moves to buy Mylan

April 21, 2015
Research and Development, Sales and Marketing India, Mylan, Perrigo, Teva, US, Vigodman, generics, israel, merger

Israeli generics drug giant Teva has made an offer to buy its US rival Mylan for around $40.1 billion. The …

News
Daiichi image

Daiichi Sankyo to sell Sun Pharma stake

April 21, 2015
Manufacturing and Production, Sales and Marketing Daiichi Sankyo, FDA, India, Ranbaxy, Sun Pharma, generics

Daiichi Sankyo is to sell off all or part of its stake in Sun Pharma and back away from the …

News

Sun Pharma and Ranbaxy merger gets US nod

February 2, 2015
Manufacturing and Production, Sales and Marketing India, Ranbaxy, Sun Pharma, US, generics, merger, recall, torrent

The US Federal Trade Commission has given its approval for Sun Pharma’s $4 billion acquisition of troubled Indian firm Ranbaxy …

News
Actavis image

Actavis buys generics firm for £306 million

January 26, 2015
Manufacturing and Production, Sales and Marketing Actavis, Allergan, Auden McKenzie, generics

Actavis is buying UK-based development and marketing firm Auden McKenzie in a deal worth up to £306 million. The move …

News
Yitzhak Peterburg image

New Teva chairman announced

November 28, 2014
Manufacturing and Production, Sales and Marketing Phillip Frost, Teva, Yitzhak Peterburg, barer, generics, israel

Teva Pharmaceutical Industries has confirmed that Professor Yitzhak Peterburg is to serve as its new chairman from January. Peterburg who …

News

UCB sells generics business

November 10, 2014
Manufacturing and Production, Sales and Marketing Belgium, UCB, generics, kremers urban, us conern

UCB is to sell its US generics business Kremers Urban to two private equity firms in a $1.5 billion deal. …

News

Latest content

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023